Arrowhead Pharmaceuticals Inc (ARWR)

NASDAQ
89.51
+1.42(+1.61%)
After Hours
89.51
0.00(0.00%)
- Real-time Data
  • Volume:
    705,774
  • Bid/Ask:
    89.00/89.99
  • Day's Range:
    88.48 - 90.41

ARWR Overview

Prev. Close
88.09
Day's Range
88.48-90.41
Revenue
89.12M
Open
88.69
52 wk Range
32.86-93.66
EPS
-1.07
Volume
705,774
Market Cap
9.17B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
713,664
P/E Ratio
-
Beta
1.25
1-Year Change
125.13%
Shares Outstanding
104,084,876
Next Earnings Date
Aug 10, 2021
What is your sentiment on Arrowhead Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Arrowhead Pharmaceuticals Inc News

Arrowhead Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsBuyStrong BuyBuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Arrowhead Pharmaceuticals Inc Company Profile

Arrowhead Pharmaceuticals Inc Company Profile

Employees
232

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Read More
  • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
    0
    • Dilution soon?
      0
      • i think they just got a ton of $ from their new deal...doesn't mean won't dilute
        0
    • Going to 69
      0
      • Target price 76$
        1
        • Upgrade?
          0
      • Pandemic covid19 Coronavirus has created massive never ever earning opportunities for biotechs pharmaceutical companies products investments...as its 7bn human beings effected need to be protected cured...supposing usd 100 each one spends on vaccines gloves sanitizers masks its huge mount Everest of earnings for biotechs pharma vaccines companies
        1
        • All pharma biotechs to shoot upwards rocket drive like Arrowhead today.....Trump clearly pushing forward indicating Coronavirus stimulus update: Trump suggests he could back bigger relief billhttps://www.cnbc.com/id/106704892?view=story?__source=androidappshare
          0
          • Go for 57$
            0
            • Go for 20$
              2
              • it is a buy now
                0
                • It's a buy
                  0
                  • to hit
                    0
                    • it looks that it is going to hot mid 70's
                      0
                      • anyone thinking shorting this stock soon? seems overbought?
                        4
                        • The increase is upnormal . Gambling
                          0
                          • back to 2014 highs?
                            0
                            • hi!
                              0
                              • Like a bargain at $16.34
                                0
                                • It did!
                                  0
                                  • ready to explode
                                    0
                                    • posted at 1.20 it will go to 4.0 guaranteed
                                      0
                                    • Stock twit
                                      0
                                    • It did...boom!
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.